Condition: Prostate Cancer

Study Type: Observational

Clinical Trials Identifier NCT 8-digits: NCT07184970

Sponsor: NYU Langone Health

Phase:

Eligibility:

• Age: minimum 40 Years maximum 95 Years
• Gender: Male

Inclusion Criteria:

• Male patients 40-95 years of age with biopsy-confirmed localized prostate cancer.
• Grade Group ≥2 (Gleason score 3+4 or higher).
• Unifocal disease visible on mpMRI.
• Patients undergoing HIFU as part of their standard of care
• PSA <20 ng/mL.
• No metastatic disease on PSMA PET/CT
• Willingness to comply with follow-up protocols (PSA testing, imaging, biopsies).

Exclusion Criteria:

• Evidence of metastatic disease on PSMA PET/CT.
• Allergy to POSLUMA or gadolinium.
• Inability to tolerate MRI due to claustrophobia or posture/back-hip issues.

View trial on ClinicalTrials.gov